Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials

Circulation - United States
doi 10.1161/circulationaha.112.105890
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Ovid Technologies (Wolters Kluwer Health)

Related search

Validation of the 6-Minute Walk in Patients With Pulmonary Arterial Hypertension: Trying to Fit a Square Peg Into a Round Hole?

Circulation
Cardiovascular MedicinePhysiologyCardiology
2012English

EXPRESS: Novel Dose-Response Analyses of Treprostinil in Pulmonary Arterial Hypertension and Its Effects on 6-Minute Walk Distance and Hospitalizations

Pulmonary Circulation
PulmonaryRespiratory Medicine
2020English

Alternatives to the Six-Minute Walk Test in Pulmonary Arterial Hypertension

PLoS ONE
Multidisciplinary
2014English

What Can Be Learned in 6 Minutes? 6-Minute Walk Test Primer and Role in Pulmonary Arterial Hypertension

Advances in Pulmonary Hypertension
2010English

6 Minute Walk Test and Idiopathic Pulmonary Fibrosis: Distance or Desaturation? A Prospective Observational Study

Journal of Medicine and Therapeutics
2017English

Validation of Impedance Cardiography in Pulmonary Arterial Hypertension

Clinical Physiology and Functional Imaging
MedicinePhysiology
2017English

Clinical End-Points and Surrogate Markers of Pulmonary Arterial Hypertension in the Light of Evidence-Based Treatment

Anadolu Kardiyoloji Dergisi/The Anatolian Journal of Cardiology
2010English

Interleukin-6 as a Potential Therapeutic Target for Pulmonary Arterial Hypertension

International Journal of Rheumatology
RheumatologyImmunology
2010English

Automated 6-Minute Walk Test Distance Measurement and Walk Characterisation Using a Novel Infrared Sensor-Based Technique

Sains Malaysiana
Multidisciplinary
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy